Skip to search formSkip to main contentSkip to account menu

recombinant vaccinia-NY-ESO-1 vaccine

Known as: rV-NY-ESO-1, vaccinia-NY-ESO-1 vaccine 
A cancer vaccine consisting of a recombinant vaccinia viral vector encoding an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
MP63-19 IMMUNOGENICITY INVESTIGATION ON RECOMBINANT BCG CONTAINING NY-ESO-1 UPON VACCINATION
INTRODUCTION AND OBJECTIVES: Bladder cancer is one of the most common malignant tumors in the urinary system. Intravesical… 
2016
2016
Abstract A169: NY-ESO-1 protein cancer vaccine with TLR 3 and 4 agonists
NY-ESO-1 is expressed in wide range of human malignancies expect testis in normal tissues and induces spontaneous antibody in… 
2014
2014
Cancer-Testis Antigene der MAGE-A Familie und NY-ESO-1 sind unabhängige prognostische Marker für ein schlechtes Gesamtüberleben bei Kopf-Hals-Tumorpatienten
2007
2007
CD8 + T-Cell Response to NY-ESO-I: Relative Antigenicity and in Vitro Immunogenicity of Natural and Analogue Sequences 1
We have shown previously that HLA-A*0201 melanoma patients can frequently develop a CTL response to the cancer testis antigen NY… 
2003
2003
Vaccines against NY-ESO-1: Peptides and recombinant viral constructs
Peptides derived from human cancer antigens have proven successful for the induction and the monitoring of antigen-specific CD8… 
2002
2002
Expression of tumor-associated antigens MAGE, NY-ESO-1 and HER-2 in patients with relapsing invasive ductal breast cancer: an immunohistochemical study
By using monoclonal antibodies (mab) specific to HER-2 protein (Hercep Test DAKO, no. K5204), to MAGE family gene products (57B… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)